-+ 0.00%
-+ 0.00%
-+ 0.00%

*Replimune : FDA Accepted for Review BLA Resubmission for RP1 (Vusolimogene Oderparepvec) in Combo With Nivolumab for Advanced Melanoma>REPL

Dow Jones·06/29/2026 12:03:00

Please log in to view news